Paromomycin Sulfate Capsules, USP

Paromomycin Sulfate by

Drug Labeling and Warnings

Paromomycin Sulfate by is a Prescription medication manufactured, distributed, or labeled by Sun Pharmaceutical Industries, Inc.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

PAROMOMYCIN SULFATE- paromomycin sulfate capsule 
Sun Pharmaceutical Industries, Inc.

----------

Paromomycin Sulfate Capsules, USP

DESCRIPTION

Paromomycin sulfate is a broad spectrum antibiotic produced by Streptomyces riomosus var. paromomycinus. It is a white, amorphous, stable, water-soluble product. Paromomycin sulfate is designated chemically as O-2,6-Diamino-2,6-dideoxy-β-L-idopyranosyl-(1→3)-O-β-D- ribofuranosyl-(1→5)-O-[2-amino-2-deoxy-α-D-glucopyranosyl-(1→4)]-2-deoxystreptamine sulfate (salt). The molecular formula is C23H45N5O14 xH2SO4, with a molecular weight of 615.64 (base). Its structural formula is:

Paromomycinsulfate-figure

Each capsule, for oral administration, contains paromomycin sulfate equivalent to 250 mg paromomycin. Each capsule also contains the following inactive ingredients: FD&C Green #3; FD&C Yellow #5 (tartrazine); gelatin, NF; and titanium dioxide, USP.

CLINICAL PHARMACOLOGY

The in vitro and in vivo antibacterial action of paromomycin closely parallels that of neomycin. It is poorly absorbed after oral administration, with almost 100% of the drug recoverable in the stool.

INDICATIONS AND USAGE

Paromomycin sulfate is indicated for intestinal amebiasis—acute and chronic (NOTE—It is not effective in extraintestinal amebiasis); management of hepatic coma—as adjunctive therapy.

CONTRAINDICATIONS

Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.

PRECAUTIONS

The use of this antibiotic, as with other antibiotics, may result in an overgrowth of nonsusceptible organisms, including fungi. Constant observation of the patient is essential. If new infections caused by nonsusceptible organisms appear during therapy, appropriate measures should be taken.

The drug should be used with caution in individuals with ulcerative lesions of the bowel to avoid renal toxicity through inadvertent absorption.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

ADVERSE REACTIONS

Nausea, abdominal cramps, and diarrhea have been reported in patients on doses over 3 g daily.

DOSAGE AND ADMINISTRATION

Intestinal amebiasis: Adults and Children: Usual dose—25 to 35 mg/kg body weight daily, administered in three doses with meals, for five to ten days.

Management of hepatic coma: Adults: Usual dose—4 g daily in divided doses, given at regular intervals for five to six days.

HOW SUPPLIED

Paromomycin Sulfate Capsules, each contain paromomycin sulfate equivalent to 250 mg paromomycin. The capsule is green/yellow, imprinted "175" in black ink on the cap and body.

NDC: 57664-175-08: Bottles of 100

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Protect from moisture.

Caution—Federal law prohibits dispensing without prescription.

Manufactured by:

ALKALOIDA Chemical Company Zrt.
4440 Tiszavasvári

Kabay János u. 29.

Hungary

Distributed by:

Sun Pharmaceutical Industries, Inc.

Cranbury, NJ 08512

Revised: 04/2015

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Paromomycin Capsules, USP 250 mg
NDC: 57664-175-08
Rx Only
100 Tablets
ALKALOIDA Chemical Company Zrt.

Paromomycinsulfate-250mg

PAROMOMYCIN SULFATE 
paromomycin sulfate capsule
Product Information
Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 57664-175
Route of AdministrationORAL
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
PAROMOMYCIN SULFATE (UNII: 845NU6GJPS) (PAROMOMYCIN - UNII:61JJC8N5ZK) PAROMOMYCIN SULFATE250 mg
Inactive Ingredients
Ingredient NameStrength
FD&C GREEN NO. 3 (UNII: 3P3ONR6O1S)  
FD&C YELLOW NO. 5 (UNII: I753WB2F1M)  
GELATIN, UNSPECIFIED (UNII: 2G86QN327L)  
TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
Product Characteristics
ColorGREEN, YELLOWScoreno score
ShapeCAPSULESize19mm
FlavorImprint Code 175
Contains    
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC: 57664-175-08100 in 1 BOTTLE; Type 0: Not a Combination Product06/30/199706/30/2017
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA06417106/30/199706/30/2017
Labeler - Sun Pharmaceutical Industries, Inc. (146974886)
Establishment
NameAddressID/FEIBusiness Operations
Sun Pharmaceutical Industries, Inc.146974886MANUFACTURE(57664-175) , PACK(57664-175)

Revised: 12/2019
 
Sun Pharmaceutical Industries, Inc.